Correlation Engine 2.0
Clear Search sequence regions


Neuroendocrine tumors (NETs) occur throughout the body, and share similar histologic characteristics. However, it has become increasingly evident that pancreatic NETs tend to respond differently to therapeutic agents than do other NET subtypes. In most cases, systemic therapy has been more effective in NETs of pancreatic origin than in NETs arising from other locations. Traditional systemic treatment options for pancreatic NETs include somatostatin analogs or cytotoxic chemotherapy. Recently, the biologically targeted agents everolimus and sunitinib were approved for use in patients with metastatic disease. Novel agents, as well as novel drug combinations, are currently under investigation. Copyright © 2013 Elsevier Inc. All rights reserved.

Citation

Matthew H Kulke. Systemic therapy for advanced pancreatic neuroendocrine tumors. Seminars in oncology. 2013 Feb;40(1):75-83

Expand section icon Mesh Tags

Expand section icon Substances


PMID: 23391115

View Full Text